Schizophrenia Daily News Blog

Bifeprunox (new drug) status update

A recent analyst presentation by Solvay pharmaceuticals suggests the their new schizophrenia drug (Bifeprunox) is moving forward.

In the report it stated:

"There was no new research announced on bifeprunox, an atypical antipsychotic drug, although Solvay noted that headline data from its full Phase III program (three placebo-controlled trials and two active reference controlled studies in around 2,600 patients) will be released before year-end. The Lehman analysts forecast a 40% probability of a launch in 2007 and worldwide peak turnover of $ 1.5 billion."

Source: PharmaMarketletter